81. Information About EORTC Protocols remission induction chemotherapy followed by an autologous or allogeneic bone marrowtransplantation for bad prognosis myelodysplastic syndromes (MDS) and http://www.eortc.be/protoc/listprot.asp?kind=sites&site=18

82. Myelodysplastic Syndromes myelodysplastic syndromes. Back to previous level Anemia, Refractory1 more specific term/s, 0 more link/s Search PUBMED for Anemia http://www.ohsu.edu/cliniweb/C15/C15.378.190.625.html

Myelodysplastic Syndromes Back to previous level Anemia, Refractory [1 more specific term/s, more link/s] Search PUBMED for Anemia, Refractory: All Review Therapy Diagnosis Anemia, Sideroblastic Search PUBMED for Anemia, Sideroblastic: All Review Therapy Diagnosis ... ANEMIA, SIDEROBLASTIC, AND SPINOCEREBELLAR ATAXIA; ASAT Hemoglobinuria, Paroxysmal Search PUBMED for Hemoglobinuria, Paroxysmal: All Review Therapy Diagnosis ... PHOSPHATIDYLINOSITOL GLYCAN, CLASS A; PIGA Leukemia, Myeloid Search PUBMED for Leukemia, Myeloid: All Review Therapy Diagnosis ... NCI/PDQ Physician Statement: Childhood acute myeloid leukemia: U. of Pennsyvania Oncolink

83. BACKGROUND OF THE DISEASE CALLED MYELODYSPLASTIC SYNDROMES OR MDS BACKGROUND OF THE DISEASE CALLED myelodysplastic syndromes OR MDSMyelodysplasticsyndromes is not a single disease, but a group of disorders primarily http://www.myelodysplasticsyndrome.com/Clinical_Presentation.html

BACKGROUND OF THE DISEASE CALLED MYELODYSPLASTIC SYNDROMES OR MDS: Myelodysplastic syndromes is not a single disease, but a group of disorders primarily affecting the bone marrow, with the abnormality most prominently reflected in a lowering of blood counts. There are two main forms of blood cells; lymphoid and myeloid. MDS, as the name implies, is a disease of the myeloid cells. The term simply means that the myeloid blood cells in the blood (as opposed to lymphoid), and their precursors in the bone marrow, look abnormal (dysplastic). The disease usually strikes older individuals, about half the patients being more than 65 years of age. There are two types of MDS, one for which no cause is known called primary MDS, and the other which follows known and documented exposure to toxic/chemical agents such as chemotherapy or radiation, called secondary MDS. The vast majority of patients constituting approximately 90% in all, belong to the primary MDS category, while in 10% cases, the disease is a result of damage to the marrow produced by chemicals such as chemotherapy for a prior malignancy or exposure to radiation. Patients invariably present with low blood counts.

84. DIAGNOSIS - MYELODYSPLASTIC SYNDROMES myelodysplastic syndromes The myelodysplastic syndromes are a group of marrow diseasescharacterized by progressive decline in the blood counts and potential http://www.hackensackstemcell.com/adult-diagnosis/myelody.html

MYELODYSPLASTIC SYNDROMES The myelodysplastic syndromes are a group of marrow diseases characterized by progressive decline in the blood counts and potential conversion to acute leukemia. These diseases are more common in the elderly and may be related to prior chemical or radiation damage. Most patients first discover their disease when they have recurrent infections, bleeding or extreme fatigue. As the bone marrow fills up with abnormal cancer cells (known as blasts) or the bone marrow becomes more abnormal (dysplastic), the normal bone marrow cells decrease in number. Thus patients may have low numbers of red blood cells (the cells that carry oxygen and nutrients), low numbers of platelets (the cells that help with clotting), and low numbers of normal white blood cells (the cells that fight infections). The prognosis of these diseases is quite variable. Refractory anemia (with or without ringed sideroblasts) is a slowly progressive disease with survivals often in the range of 7-10 years. Refractory anemia with blasts (excess or blasts in transition) are much more aggressive diseases in which patients are at risk of immediate infection and bleeding complications and diseases which may progress to leukemia in under 2 years. Treatment of the myelodysplastic diseases has been quite difficult. Many patients are too old to withstand aggressive therapy such as chemotherapy. Transfusions of blood and antibiotic treatments are common. In younger patients, combination chemotherapy (which medications such as topotecan and cytarabine) may result in temporary remissions.

85. SOTS Myelodysplastic Syndrome Conference Oct. 30 - 31, 2000 and agents Immunosuppressive therapy shows promise in MDS based on similarity toaplastic anemia and other bone marrow failure syndromes - Studies of growth http://www.webtie.org/sots/Meetings/Leukemia/10-30-2000/Default.htm

Key Questions What are the appropriate molecular targets for therapy of MDS? - How should new agents be studied? - Which standard treatments should be used for comparison? Are there true differences between the subtypes of MDS? How should response to new targeted therapies be assessed in clinical trials? Outcomes and Discussion Points Develop targets based on biology of hematopoiesis and apoptosis - Target areas: (1) proliferation and differentiation; (2) apoptosis vs. survival; (3) ligand-receptor interactions; and (4) homing or migration of cell - Targets based on disease etiology theory - Initiating genetic event (either somatically acquired or inherited) - Genetic progression with immune phenomenon - Secondary epiphenomenon (e.g., apoptosis, cytokines) - Target treatment at epiphenomenon until genetic pathways are understood Epidemiology and molecular genetics - Include epidemiologic studies in the design of future MDS trials - Apply comprehensive molecular/protein-based strategies to develop patterns to study MDS - Broader identification of single target genes for MDS are necessary, especially a target gene for the phenomenon of haplo-insufficiency for clonal disease

86. Second International Congress Myeloproliferative Diseases And Myelodysplastic Sy Second International Congress Myeloproliferative Diseases And MyelodysplasticSyndromes First Announcement Call for Abstracts. Hilton http://www.imedex.com/announcements/silver03.htm

Second International Congress Myeloproliferative Diseases And Myelodysplastic Syndromes First Announcement Call for Abstracts Hilton New York October 16-18, 2003 New York, New York Chairmen Registration Hours Conference Location Scientific Program ... Conference Objectives Organizing Committee Chair: Richard T. Silver, M.D. Cornell University Medical College New York, New York Vice Chair: Jerry L. Spivak, M.D. Johns Hopkins University School of Medicine Baltimore, Maryland Conference Location Meeting and commercial exhibit location: Hilton New York 1335 Avenue of the Americas New York, New York 10019 Tel.: +1 (212) 586 7000 Fax: +1 (212) 315 1374 Conference Support Sponsorship opportunities are available to companies interested in supporting this conference. For details, please contact Piper Gray at at +1 (770) 751 7332 or send e-mail to sponsor@imedex.com Chairmen Conference Location Conference Support ... Home Conference Organizer education is the best medicine 70 Technology Drive Alpharetta, GA

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 5     81-86 of 86    Back | 1  | 2  | 3  | 4  | 5